BioStem Technologies (BSEM) vs Edesa Biotech (EDSA)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Edesa Biotech (EDSA) has outperformed BioStem Technologies (BSEM) over the past year, gaining 34.6% versus a loss of 45.0%. Over five years, BSEM leads with a +88.6% price change compared with -93.3% for EDSA. Edesa Biotech is the larger company by market cap ($49.5 million vs $49.3 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | BSEM | EDSA |
|---|---|---|
| Share price | $2.64 | $3.66 |
| Market cap | $49.29M | $49.45M |
| 1-day change | +10.46% | -5.79% |
| YTD return | -30.71% | +157.75% |
| 1-year return | -45.00% | +34.56% |
| 5-year return | +88.57% | -93.31% |
| P/E ratio (TTM) | 3.00 | — |
| Forward P/E | 9.10 | — |
| EPS (TTM) | $0.88 | $-1.72 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $8.40 | $20.32 |
| 52-week low | $2.25 | $0.72 |
| Distance from 52-week high | -68.57% | -81.99% |
| Analyst consensus | none | none |
| Avg. price target upside | +165.15% | +346.17% |
| Average volume | 124.14K | 61.89K |
| Shares outstanding | 18.67M | 13.51M |
| Employees | 73 | 17 |
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Biotechnology |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- EDSA has outperformed BSEM by 79.6 percentage points over the past year.
About BioStem Technologies
BSEM stock →BioStem Technologies, Inc. engages in the development, manufacturing, and commercialization of placental-derived allografts for advanced wound care and regenerative therapies in the United States.
Healthcare · Biotechnology · 73 employees
About Edesa Biotech
EDSA stock →Edesa Biotech, Inc., a clinical-stage biopharmaceutical company, engages in the research and development, manufacture, and commercialization of pharmaceutical products for inflammatory and immune-related diseases. It develops EB05, a monoclonal antibody, which is in Phase 3 clinical study for the treatment of acute respiratory distress syndrome; and EB01, a topical vanishing cream containing non-steroidal anti-inflammatory compound that has completed Phase 3 clinical study to treat chronic allergic contact dermatitis.
Healthcare · Biotechnology · 17 employees
BSEM vs EDSA FAQ
Which is bigger, BioStem Technologies or Edesa Biotech?
Edesa Biotech (EDSA) is larger, with a market capitalization of $49.45M compared with $49.29M for BioStem Technologies (BSEM).
Which stock has performed better over the past year, BSEM or EDSA?
EDSA returned +34.56% over the past 12 months, compared with -45.00% for BSEM (price return, excluding dividends). Past performance does not predict future results.
Are BioStem Technologies and Edesa Biotech in the same industry?
Yes. Both are classified in the Biotechnology industry within the Healthcare sector.